WO2006114702A3 - Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor - Google Patents

Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor Download PDF

Info

Publication number
WO2006114702A3
WO2006114702A3 PCT/IB2006/001040 IB2006001040W WO2006114702A3 WO 2006114702 A3 WO2006114702 A3 WO 2006114702A3 IB 2006001040 W IB2006001040 W IB 2006001040W WO 2006114702 A3 WO2006114702 A3 WO 2006114702A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pharmaceutical compositions
aromatase inhibitor
combination
phenyl
Prior art date
Application number
PCT/IB2006/001040
Other languages
French (fr)
Other versions
WO2006114702A2 (en
Inventor
Madelyn Curto
Melanie Sisson
Andrew George Lee
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Madelyn Curto
Melanie Sisson
Andrew George Lee
David Duane Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Madelyn Curto, Melanie Sisson, Andrew George Lee, David Duane Thompson filed Critical Pfizer Prod Inc
Priority to CA002605796A priority Critical patent/CA2605796A1/en
Priority to EP06744583A priority patent/EP1937251A2/en
Publication of WO2006114702A2 publication Critical patent/WO2006114702A2/en
Publication of WO2006114702A3 publication Critical patent/WO2006114702A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-(-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug thereof and an aromatase inhibitor. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8- tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug and an aromatase inhibitor selected from aminoglutethimide; formestane; atamestane; anastrazole; fadrozole; finrozole; letrozole; vorozole; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole or exemestane, or a pharmaceutically acceptable salt thereof.
PCT/IB2006/001040 2005-04-25 2006-04-13 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor WO2006114702A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002605796A CA2605796A1 (en) 2005-04-25 2006-04-13 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
EP06744583A EP1937251A2 (en) 2005-04-25 2006-04-13 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67480705P 2005-04-25 2005-04-25
US60/674,807 2005-04-25

Publications (2)

Publication Number Publication Date
WO2006114702A2 WO2006114702A2 (en) 2006-11-02
WO2006114702A3 true WO2006114702A3 (en) 2007-01-04

Family

ID=36693972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001040 WO2006114702A2 (en) 2005-04-25 2006-04-13 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Country Status (6)

Country Link
EP (1) EP1937251A2 (en)
JP (1) JP2006306872A (en)
AR (1) AR054258A1 (en)
CA (1) CA2605796A1 (en)
TW (1) TW200716094A (en)
WO (1) WO2006114702A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711525A2 (en) 2006-06-02 2011-11-01 Pear Tree Women S Health Care Pharmaceutical composition and method for treating symptoms of atrophic vaginitis
EP2070943A1 (en) * 2007-12-14 2009-06-17 Crystal Pharma, S.A. Process for obtaining 6-Alkylidenandrost-1,4-diene-3one
WO2011002096A1 (en) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Labeling compound for pet
AU2012304694B2 (en) 2011-09-08 2016-04-07 Mereo Biopharma 2 Limited Pharmaceutical compositions comprising an aromatase inhibitor
EP4029950A1 (en) 2016-04-29 2022-07-20 Board of Regents, The University of Texas System Targeted measure of transcriptional activity related to hormone receptors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
WO2002020000A2 (en) * 2000-09-08 2002-03-14 Sloan-Kettering Institute For Cancer Research Combined estrogen blockade of the breast with exemestane and raloxifene
WO2003017973A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
WO2003032961A2 (en) * 2001-10-10 2003-04-24 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
US20040024044A1 (en) * 2000-09-08 2004-02-05 Di Salle Enrico Exemestane as chemopreventing agent
WO2005070434A2 (en) * 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
WO2006048749A1 (en) * 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
WO2002020000A2 (en) * 2000-09-08 2002-03-14 Sloan-Kettering Institute For Cancer Research Combined estrogen blockade of the breast with exemestane and raloxifene
US20040024044A1 (en) * 2000-09-08 2004-02-05 Di Salle Enrico Exemestane as chemopreventing agent
WO2003017973A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
WO2003032961A2 (en) * 2001-10-10 2003-04-24 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
WO2005070434A2 (en) * 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
WO2006048749A1 (en) * 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Also Published As

Publication number Publication date
AR054258A1 (en) 2007-06-13
TW200716094A (en) 2007-05-01
JP2006306872A (en) 2006-11-09
CA2605796A1 (en) 2006-11-02
WO2006114702A2 (en) 2006-11-02
EP1937251A2 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
JP2010521483A5 (en)
ATE504565T1 (en) AZETIDINES AS MEK INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES
CY1109860T1 (en) FACTORS OF HISTAMIN H3 CONTAINERS, PREPARATION AND THERAPEUTIC USES
ATE371656T1 (en) HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
NO20056192L (en) Capase inhibitors and their use
NO20060981L (en) Pyridazine derivatives and their use as therapeutic agents
EE200300403A (en) N-substituted Non-Aromatic Heterocyclic Compound, Pharmaceutical Composition Containing It, and Use of the Compound as a Pharmaceutical
WO2007087066A3 (en) 1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
EA200601747A1 (en) THREE (CYCLO) SUBSTITUTED AMIDA COMPOUNDS
NZ626985A (en) Combination therapy (vemurafenib and a mdm2 inhibitor) for the treatment proliferative disorders
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
UA94427C2 (en) Pharmaceutical composition for the topical treatment of ocular neovascular disorders
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
NO20081970L (en) Sulfonamide derivatives with PGD2 receptor antagonist activity
WO2006114702A3 (en) Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CA2409741A1 (en) Tnf-.alpha. production inhibitors
RU2009118254A (en) PHENYLACETAMIDES AS PROTEINKINASE INHIBITORS
MX2010004501A (en) 5-lipoxygenase activating protein (flap) inhibitor.
NO20060020L (en) 3-fluoropiperidines as NMDA / NR2B antagonists
ATE384058T1 (en) THIAZOLE DERIVATIVES
NZ598918A (en) Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2605796

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006744583

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006744583

Country of ref document: EP